
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow Inc. exhibits a strong growth trajectory, highlighted by a 22% quarter-over-quarter revenue increase for its flagship product VEVYE, reaching $22.6 million in the third quarter of 2025. The company has secured a 10.5% share of the national dry eye disease market, showcasing its competitive positioning and potential for further gains, supported by ongoing prescription growth momentum. Anticipations of a quarterly revenue run rate surpassing $250 million by the fourth quarter of 2027, which would represent a significant increase compared to prior results, enhance confidence in Harrow's strategic direction and long-term margin expansion potential.
Bears say
Harrow Inc faces significant risk factors that contribute to a negative outlook on its stock, primarily centered around the potential for unfavorable clinical data and regulatory approval for products developed by its spinouts, which could diminish product opportunities and adversely impact the company’s valuation. Additionally, the company may experience lower-than-expected market uptake for its products and faces challenges in developing its pipeline, acquiring new products, and servicing its existing debt, all of which could materially affect its financial stability. Furthermore, as a small company with limited resources, Harrow Inc may be compelled to scale back on sales and marketing efforts and could require capital raises that would lead to further dilution of existing shareholders.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares